GURUFOCUS.COM » STOCK LIST » Asia » Hong Kong » HKSE » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Net Intangibles Purchase And Sale
Switch to:

InnoCare Pharma (HKSE:09969) Net Intangibles Purchase And Sale

: HK$-154 Mil (TTM As of Jun. 2022)
View and export this data going back to 2020. Start your Free Trial

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

InnoCare Pharma's net Intangibles purchase and sale for the six months ended in Jun. 2022 was HK$-154 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Jun. 2022 was HK$-154 Mil.

InnoCare Pharma Net Intangibles Purchase And Sale Historical Data

The historical data trend for InnoCare Pharma's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
Net Intangibles Purchase And Sale
- -18.70 -0.52 -0.32 -1.76

InnoCare Pharma Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Net Intangibles Purchase And Sale Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.27 -1.67 -0.07 -153.99

InnoCare Pharma Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-154 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCare Pharma Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (HKSE:09969) Business Description

InnoCare Pharma logo
Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
HKSE:01530 HKSE:06826 HKSE:09995 HKSE:02179 HKSE:02185 HKSE:02157 HKSE:09926 HKSE:09939 HKSE:02696 HKSE:01477 OCSE:NOVO B ASX:CSL NAS:REGN NAS:VRTX NAS:MRNA XKRX:207940 NAS:BNTX HKSE:02269 NAS:SGEN SZSE:300122
Traded in Other Exchanges
33C:Germany 688428:China
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 100084
Website
https://www.innocarepharma.com
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. Its commercial drug candidate is Orelabrutinib and clinical-stage drug candidates are ICP-192, ICP-105, ICP-723, and others.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines